Baker Tilly Wealth Management LLC Increases Position in Haleon plc (NYSE:HLN)

Baker Tilly Wealth Management LLC boosted its holdings in Haleon plc (NYSE:HLN) by 20.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 59,305 shares of the company’s stock after purchasing an additional 9,987 shares during the quarter. Baker Tilly Wealth Management LLC’s holdings in Haleon were worth $627,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of HLN. IMC Chicago LLC purchased a new stake in Haleon in the first quarter worth about $300,000. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Haleon by 42.5% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 66,247 shares of the company’s stock worth $562,000 after buying an additional 19,763 shares in the last quarter. Founders Financial Securities LLC bought a new position in shares of Haleon in the first quarter worth approximately $552,000. Allspring Global Investments Holdings LLC bought a new position in shares of Haleon in the first quarter worth approximately $43,000. Finally, Norden Group LLC lifted its stake in shares of Haleon by 4,086.3% in the first quarter. Norden Group LLC now owns 428,129 shares of the company’s stock worth $3,635,000 after buying an additional 417,902 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Haleon Stock Up 1.2 %

Shares of Haleon stock opened at $9.97 on Monday. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.44. Haleon plc has a twelve month low of $7.70 and a twelve month high of $10.80. The company has a market cap of $45.52 billion, a price-to-earnings ratio of 32.83, a price-to-earnings-growth ratio of 2.90 and a beta of 0.26. The company’s 50 day moving average is $10.23 and its 200 day moving average is $9.21.

Haleon (NYSE:HLN) last released its quarterly earnings results on Thursday, August 1st. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). Haleon had a return on equity of 13.15% and a net margin of 9.71%. The business had revenue of $3.50 billion during the quarter, compared to the consensus estimate of $3.55 billion. During the same quarter in the previous year, the business posted $0.08 earnings per share. Research analysts anticipate that Haleon plc will post 0.46 EPS for the current year.

Haleon Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Thursday, September 19th. Shareholders of record on Friday, August 16th were given a $0.0514 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a yield of 1.6%. Haleon’s payout ratio is presently 33.33%.

Analyst Ratings Changes

Several brokerages have recently issued reports on HLN. Berenberg Bank began coverage on shares of Haleon in a research note on Tuesday, August 6th. They issued a “buy” rating on the stock. UBS Group upgraded shares of Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. Morgan Stanley increased their price objective on shares of Haleon from $9.90 to $10.95 and gave the company an “overweight” rating in a research report on Friday, September 20th. Finally, The Goldman Sachs Group downgraded shares of Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Haleon currently has an average rating of “Buy” and a consensus target price of $10.95.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.